Procedures for chronic total occlusion: when are they recommended and when not

Mila Menozzi and Giancarlo Piovaccari*

Cardiology Unit, Infermi Hospital, Rimini

KEYWORDS
Chronic total occlusion (CTO); Viable myocardium; Reversible ischaemia; OMT (optimal medical treatment)

Coronary chronic total occlusion (CTO) produces an important clinical problem, often treated with medical therapy or coronary artery bypass grafting. Recent clinical studies, both registries and randomized trials, demonstrated that percutaneous coronary interventions (PCI), could provide a valid therapeutic option. Nonetheless, significant reduction in all-cause mortality, cardiac mortality, myocardial infarction, MACE, and MACCE has not been demonstrated in the subgroups analysis of randomized trials. These analyses suggest that PCI for CTO should be reserved for patients with angina or with large areas of the myocardium with reversible ischaemia. Large randomized studies should search for a personalized approach, considering the risks and complexity of PCI in CTO, which should mainly consider the extension of the ischaemia and the viability of the myocardium.

Definition

Chronic coronary occlusion (CTO) is defined as a complete or almost complete obstruction of an epicardial coronary vessel with TIMI 0 or 1 flow, datable for at least 3 months.¹

Prevalence of total chronic occlusions

In the activity of a catheterization laboratory with high volumes of work, the CTOs have a prevalence that varies from 18% of the Canadian Register² to 50%,³ the highest percentage we find in patients with previous coronary artery bypass graft (CABG). However, only a small percentage of these patients, after diagnosis, will undergo percutaneous unblocking (PCI). Furthermore, although there is an increase in the popularity of PCI in CTOs, the vast majority of patients are treated either with medical therapy or CABG. The Guidelines recommend considering PCI in CTOs to improve survival and quality of life but in practice the number of procedures remains low.

Treatment of total chronic occlusions

Percutaneous coronary intervention for CTO should be considered, according to the latest ESC/EACTS Guidelines,⁴ in the same way as a non-PCI CTO. This keeping in mind that the patient is subjected to an often longer procedure, which requires a higher dose of radiation and a contrast medium and with a higher complication rate.⁵

From the literature data, the potential benefits of PCI for CTO are still controversial due to the small number of randomized trials. There is therefore consensus⁶ that at least one of the following conditions is necessary to proceed with the recanalization of a CTO:

1. the presence of angina or dyspnoea limiting daily activities, with the aim of alleviating symptoms as well as increasing exercise capacity.
2. in asymptomatic or scarcely symptomatic patients the documentation of myocardial ischaemia through non-invasive imaging tests, with the aim of reducing the extent of ischaemia.
3. in patients with depressed left ventricular systolic function, the demonstration of vitality with echo-dobutamine, myocardial scintigraphy, or magnetic resonance imaging, with the aim of improving dyspnoea or signs of decompensation.
4. the presence of multivessel disease with the aim of improving the prognosis.

Symptoms and quality of life

There is evidence from non-randomized, both retrospective and prospective, studies that demonstrate how the recanalization of CTOs improves symptoms.⁷

*Corresponding author. Email: giancarlo.piovaccari@auslromagna.it

Published on behalf of the European Society of Cardiology. © The Author(s) 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
In a meta-analysis that assessed the clinical impact on angina in patients undergoing effective vs. ineffective revascularization of a CTO, there is twice the incidence of persistent angina in patients treated unsuccessfully compared to those successfully treated. It should be emphasized that the symptoms in patients with CTO often have an atypical presentation, also due to the presence of a collateral circulation that can partially reduce ischaemia. Furthermore, the chronic nature of the condition often leads the patient to slowly and progressively reduce the workload so that he rarely complains of reduced exercise capacity. In addition, patients with CTO often report exertion dyspnoea and not angina, a less specific symptom that can be attributed to potential non-cardiac causes.

Despite these diagnostic difficulties, there are comforting and solid data. The EUROCTO randomized trial evaluated the quality of life in patients with CTO and optimal medical therapy (OMT) and demonstrated a reduction in symptoms with PCI compared to OMT alone. The prospective OPEN CTO study showed that >80% of patients with CTO have dyspnoea and that revascularization of CTO improves dyspnoea in 70% of patients.

**Ischaemia**

In chronic ischaemic heart disease, an >10% myocardial ischaemic load has been shown to have an unfavourable impact on prognosis. The myocardium underlying a CTO, in the absence of previous transmural myocardial infarction, should be considered ischaemic until proven otherwise. The presence of collateral circulation, in fact, protects against necrosis but never completely prevents ischaemia. The point is to quantify the area of myocardial necrosis. The revascularization of a CTO has a strong rationale in the presence of inducible myocardial ischaemia found with imaging tests. In the case of a large epicardial vessel occluded at the level of a proximal segment in a patient with preserved left ventricular systolic function, the presence of inducible myocardial ischaemia is very likely, therefore revascularization of the CTO could be considered even if not preceded by ischaemia testing.

**Viability**

The revascularization of a CTO finds another strong indication in patients with reduced systolic function due to alterations of the segmental kinetics of the myocardial segments underlying the chronically occluded vessel. Recovery is greater the larger the hibernated or stunned but the viable myocardial area is.

Imaging tests such as myocardial scintigraphy, stress echocardiography, and cardiac magnetic resonance imaging (RMC) allow us to evaluate the viability of the myocardial territories with reduced contractility. MRI currently represents the gold standard for the assessment of myocardial viability and the transmural extension of necrosis; the measurement of the infarcted area obtained with RMC is an index that linearly correlates with the favourable remodelling of the left ventricle and the recovery of systolic function, after recanalization of a CTO. In patients with transmural necrosis extension (TNE) <75%, an increase in parietal thickening is observed in the segments underlying the recanalized CTO, while patients with TNE >75% do not show significant improvements. Therefore, the revascularization of a CTO does not have a rationale if the underlying myocardial segments have a TNE >75% as they are considered non-viable, while the lesser is the extension of transmural necrosis is higher is the benefit of the procedure.

**Prognosis**

Incomplete revascularization is known to be associated with a higher incidence of adverse events at follow-up, particularly in the presence of a residual CTO. According to the PL-ACS Registry, the CTO is a negative prognostic factor for ACS mortality. In the Horizons-AMI trial, CTO is a negative prognostic factor for mortality in ST-segment elevation myocardial infarction (STEMI). According to some authors in patients with a CTO found in the course of myocardial infarction, the recanalization of the same during a scheduled procedure is associated with lower cardiac mortality and a lower rate of adverse cardiovascular events at 2 years. The data from the Explore trial, on the other hand, do not demonstrate benefits in terms of improving the ejection fraction and reducing the left ventricular volume after scheduled revascularization of a non-culprit CTO in patients with STEMI treated with primary angioplasty.

Numerous observational studies have shown a reduction in MACE and an improvement in outcome following revascularization of CTOs in chronic ischaemic heart disease. A systematic review of 25 observational studies showed that CTO angioplasty (CTO PCI) if effective is associated with a favourable 3-year outcome in terms of survival, residual angina, and use of bypass. In a recent study analysing the prognostic impact of CTOs in patients enrolled in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the presence of a CTO is an independent mortality factor (hazard ratio 1.29; P < 0.001) and among patients undergoing an attempt to recanalization of a CTO, effective procedure is associated with significantly better survival (hazard ratio 0.85; P < 0.034). Also in the Italian IRCTO Registry (Drug-Eluting Stent Implantation vs. Optimal Medical Treatment in Patients With Chronic Total Occlusion), with a propensity analysis, patients with CTO treated with PCI show a lower incidence of death (1.5 vs. 4.4%; P < 0.001), acute myocardial infarction (1.1 vs. 2.9%; P = 0.03), and re-hospitalization (2.3 vs. 4.4% P = 0.04) compared to those treated with OMT alone.

While the results of the DECISION CTO trial do not demonstrate superiority of the PCI CTO compared to the OMT, although the numerous limitations of the study are evident: the slow enrolment and the low sample size (fewer patients than those predicted by the sample size); a high cross-over between the two arms; the inclusion of the periprocedural infarction among the endpoint. However, there is a trend towards decreasing mortality in the PCI CTO arm.

**Conclusions**

Defining the risks and benefits of a recanalization procedure is true in general, even more when it comes to recanalization. The benefit, as we have seen, is in terms of improvement of symptoms in symptomatic patients,
reduction of ischaemic burden, or improvement of ventricular function in asymptomatic patients. It should not be forgotten that the benefit derives from an effective recanalization, which stands at 85–90% in centres of experience, as opposed to 54–80% in the Registers ‘all comers’. The risk is around 3% and depends on the age of the patient, the complexity of the lesion, and the recanalization technique used, as well as the experience of the operator. Therefore, training programs for operators of and development of specific techniques of CTO PCI, continuous education through courses, live cases, and proctoring, are required.20

Conflict of interest: none declared.

References

1. Sianos G, Werner GS, Galassi AR, Papaflaki MJ, Escaned J, Hildick-Smith D, Christiansen EH, Gershlick A, Carlino M, Karlas A, Konstantinidis NV, Tomasello SD, Di Mario C, Reifart N; EuroCTO Club. Recanalisation of chronic total coronary occlusions; 2012 consensus document from the EuroCTO club. EuroInterv; 2012;8:1186-1452.

2. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, Gannot S, Samuel M, Weisbrod M, Bierstone D, Sparkes JD, Wright GA, Straus BH. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol 2012;59:991-997.

3. Jeroudi OM, Alomar ME, Michael TT, Sabbagh AE, Patel VG, Mogabgab O, Fuh E, Sherbet D, Lo N, Roelse M, Rangan BV, Abdullah SM, Hastings JL, Grodin J, Banerjee S, Brilakis ES. Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital. Catheter Cardiovasc Interv 2014;84:637-643.

4. Neumann FJ, Sousa-Uva M, Alhsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2018.

5. Brilakis ES, Banerjee S, Karmpaliotis D, Lombardi WL, Tsai TT, Shunk KA, Kennedy KF, Spterus JA, Holmes DR, Grantham JA. Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol Cardiovasc Interv 2015;8:245-253.

6. Galassi AR, Brilakis ES, Boukhris M, Tomasello SD, Sianos G, Karmpaliotis D, Di Mario C, Strauss BH, Rinfrset S, Yamane A, Kato O, Werner GS, Reifart N. Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview. Eur Heart J 2016;37:2692-2700.

7. Safley DM, Grantham JA, Hatch J, Jones PG, Spterus JA. Quality of life benefits of percutaneous coronary intervention for chronic occlusions. Catheter Cardiovasc Interv 2014;84:629-634.

8. Joyal D, Affilalo J, Rinfrset S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J 2010;160:179-187.

9. Werner GS, Martin-Yuste V, Hildick-Smith D, Boukhris M, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogarts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 2018;39:2484-2493.

10. Sapontis J, Salisbury AC, Yeh RW, Cohen DJ, Hirai T, Lombardi W, McCabe JM, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaeudy A, Cook S, Doshi P, Federici R, Thompson CR, Marsi SP, Nugent K, Gosch K, Spterus JA, Grantham JA. Early procedural and health status outcomes after chronic total occlusion angioplasty: a report from the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). J Am Coll Cardiol Cardiovasc Interv 2017;10:1523-1534.

11. Mattessini A, Valente S, Sorini Dini C, et al. Il trattamento delle occlusioni coronariche croniche: stato dell’arte. G Ital Cardiol 2017;18(e Suppl 1):35-115.

12. Camici PG, Wijns W, Borgers M, De Silva R, Ferrari R, Knutti J, Lammermata AA, Liedtke AJ, Paternostro G, Vatner SF. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997;96:3205-3214.

13. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998;339:173-181.

14. Gierlotka M, Tajstra M, Ga sier M, Hawranek M, Osadnich T, Wilczek K, Olszewski D, Dyrbus K, Poloniski L. Impact of chronic total occlusion artery on 12-month mortality in patients with non-ST-segment elevation myocardial infarction treated by percutaneous coronary intervention (from the PL-ACS Registry). Int J Cardiol 2013;168:250-254.

15. Claessen BE, Danges GD, Weisz G, Witzenbichler B, Guagliumi G, Mocelli M, Brenner SJ, Xu K, Henriques JP, Mehran R, Stone GW. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J 2012;33:768-775.

16. Yang ZK, Zhang RF, Hu J, Zhang Q, Ding FH, Shen WF. Impact of successful staged revascularization of a chronic total occlusion in the non-infarct-related artery on long-term outcome in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol 2013;165:76-79.

17. Henriques JP, Hoebers LP, Ramanndul T, Laanmets P, Eriksen B, Eriksen E, Bax M, Ioanes D, Sptturp MJ, Strauss BH, Barbato E, Niijveldt R, van Rossum AC, Marques KM, Elías J, van Dongen IM, Claessen BEPM, Tijssen JG, van der Schaaf R, Henriques JP, van der Schaaf R, Tijssen JG, Zijlstra F, de Boer M-J, Michels R, Meuwissen M, Agostini P, van Houwelingen KG, Verberne HJ, Hirsch A, Henriques JP, Piek JJ, de Winter R, Koch KT, Vis MM, Baan J, Wykrzykowska J, Ramanndul T, Ioanes D, Laanmets P, van der Schaaf R, Slagboom T, Hourou G, Eriksen B, Eriksen E, Sptturp MJ, Strauss BH, Barbato E, Marques KM, Bertrand G, Meuwissen M, van der Ent M, Koolen J. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: the EXPLORE trial. J Am Coll Cardiol 2016;68:1622-1632.

18. Ramanndul T, Hoebers LP, Henriques JP, et al. Prognostic impact of chronic total occlusions: a report from SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol Cardiovasc Interv 2016;10:1535-1544.

19. Lee S-W, Lee PH, Ahn J-M, Park D-W, Yoon S-C, Han S, Kang H, Kang S-J, Kim Y-H, Lee CW, Park S-W, Huh SH, Rha S-W, Her S-H, Choi SW, Lee B-K, Lee N-H, Lee J-Y, Cheong S-S, Kim MH, Ahn Y-K, Lim SW, Lee S-G, Hiremath S, Santosu T, Udajachewlum W, Cheng JJ, Cohen DJ, Moratamusi T, Tsichukane E, Asakura Y, Park S-J. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion: the DECISION-CTO trial. Circulation 2019;139:1674-1683.

20. Brilakis ES, Mashayekhi K, Tsichukane E, Abi Rafeh N, Alassad K, Araya M, Arvan A, Azzalini L, Babunashvili AM, Bayani B, Bhindi R, Boudou N, Boukhris M, Bozinovic NZ, Bryniarski L, Bufe A, Buller CE, Burke MN, Bttner HJ, Cardoso P, Carlino M, Christiansen EH, Colombo A, Croce K, Damas de los Santos F, De Martini T, Dens J, Di Mario C, Dou K, Egred M, Elguindy AM, Escaned J, Furkalo S, Gagnon A, Galassi AR, Garbo R, Ge J, Goel PK, Goktekin O, Grancini L, Grantham JA, Hanratty C, Hard S, Harding SA, Henriques JPS, Hill JM, Jaffer FA, Jiang Y, Jussila R, Kalnins A, Kalyanasundaram A, Kandzari DE, Kao H-L, Karmpaliotis D, Kassem HH, Knaepen P, Kornowsky R, Krestyninov O, Kumar AVG, Laanmets P, Lamelas P, Lee S-W, Lefevre T, Li Y, Lim S-T, Lo S, Lombardi W, McIntegart M, Munawar M, Navarro Lecaro JA, Ngo HM, Nicholson W, Olivecrona L, Olsson SM, Ogata SM, Onyango S, Olszewski D, Perbet S, Philipson SM, Ramandul T, Santosu T, Suttorp M, de Winter RJ, Koolen J. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: the EXPLORE trial. J Am Coll Cardiol 2016;68:1622-1632.